Bank of America Corp DE Sells 418,992 Shares of Qiagen N.V. $QGEN

Key Points

• Bank of America reduced its Qiagen stake by 11.4%, selling 418,992 shares in the first quarter and retaining 3.25 million shares worth approximately $130 million. Institutional investors own about 70% of Qiagen.
• Analyst sentiment is mixed, with one Strong Buy, four Buy, eight Hold and one Sell rating. The consensus rating is Hold, with an average price target of $42.43 versus the reported share price of $41.71.
• Qiagen exceeded second-quarter expectations with adjusted EPS of $0.62 and revenue of $535 million, while reaffirming full-year EPS guidance of approximately $2.43. However, third-quarter and full-year revenue guidance came in below analyst expectations.

Bank of America Corp DE reduced its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 11.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,246,973 shares of the company's stock after selling 418,992 shares during the period. Bank of America Corp DE owned about 1.58% of Qiagen worth $130,009,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Danske Bank A S bought a new stake in Qiagen in the 3rd quarter worth about $36,000. Manchester Capital Management LLC purchased a new position in Qiagen in the 4th quarter worth about $42,000. Global Retirement Partners LLC lifted its stake in Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company's stock valued at $52,000 after acquiring an additional 851 shares during the period. Advisory Services Network LLC bought a new position in Qiagen during the 3rd quarter valued at about $64,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Qiagen during the 4th quarter valued at about $70,000. 70.00% of the stock is owned by institutional investors.

Analysts Set New Price Targets

QGEN has been the subject of a number of research analyst reports. Robert W. Baird set a $43.00 price target on shares of Qiagen and gave the stock an "outperform" rating in a research note on Wednesday, April 29th. Weiss Ratings downgraded shares of Qiagen from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, May 29th. JPMorgan Chase & Co. dropped their target price on shares of Qiagen from $60.00 to $45.00 and set an "overweight" rating on the stock in a report on Wednesday, April 29th. Citigroup reaffirmed a "hold" rating on shares of Qiagen in a research report on Monday, May 18th. Finally, TD Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $42.43.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $41.71 on Friday. The firm has a 50 day moving average of $39.32 and a 200 day moving average of $41.69. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $8.59 billion, a price-to-earnings ratio of 21.37, a price-to-earnings-growth ratio of 4.19 and a beta of 0.63. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The business had revenue of $535.00 million during the quarter, compared to analysts' expectations of $527.50 million. During the same period in the prior year, the company earned $0.60 earnings per share. The firm's revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, research analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were paid a $0.35 dividend. This is a positive change from Qiagen's previous annual dividend of $0.26. The ex-dividend date was Tuesday, July 7th. This represents a dividend yield of 90.0%. Qiagen's dividend payout ratio (DPR) is currently 18.32%.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen reported second-quarter adjusted EPS of $0.62, above the $0.60 consensus estimate, while revenue of $535 million exceeded expectations of $527.5 million. Revenue was broadly unchanged year over year, but the company said its growth pillars delivered 5% growth at constant exchange rates and that sales exceeded its prior outlook for a decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 EPS outlook of approximately $2.43, in line with analyst expectations, while maintaining high profitability. Qiagen Earnings Conference Call
• Neutral Sentiment: Management’s second-quarter earnings call and presentation provided additional detail on the performance of Qiagen’s growth pillars and the company’s outlook, but did not materially change the full-year EPS forecast. Qiagen N.V. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter guidance was below consensus: EPS of $0.62 versus $0.63 expected and revenue of $538.3 million to $543.7 million versus $552.7 million expected. The revenue shortfall indicates analysts may need to reduce near-term estimates.
• Negative Sentiment: Although full-year EPS guidance matched consensus, full-year revenue guidance of roughly $2.1 billion was below the approximately $2.2 billion analyst estimate, tempering the impact of the quarterly beat.

Qiagen Company Profile

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source